Iván Garcia tercero

Dr. Iván Garcia tercero


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2012 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
DLDiana Lacruz-Guzmán
Diana Lacruz-Guzmán
DTDaniel Torres-Moreno
Daniel Torres-Moreno
FPFrancisco Pedrero
Francisco Pedrero
PRPatricia Romero-Cara
Patricia Romero-Cara
ITIván Garcia tercero
Iván Garcia tercero
PCPablo Conesa-Zamora
Pablo Conesa-Zamora

3 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMaría Chaparro
María Chaparro
IBIria Baston-Rey
Iria Baston-Rey
ESEstela Fernández Salgado
Estela Fernández Salgado
JGJavier González García
Javier González García
Laura RamosLaura Ramos
Laura Ramos
JGJavier P Gisbert
Javier P Gisbert
Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients’ data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.